Alchemia (ACL)

**tommy** · 21-10-2004, 04:57 PM

New drug! UP 49.06%! Lovely baby

**tommy** · 21-10-2004, 05:24 PM

21 October 2004

ASX / MEDIA RELEASE

Breakthrough for Alchemia antibiotic drug discovery technology
Australian biotechnology company Alchemia Limited (ASX: ACL) today
announced a significant breakthrough for the antibiotic stream of its early
stage drug discovery platform.
Independent test results have confirmed that Alchemia’s novel class of
antibiotic compounds have a unique mechanism of action that could
revolutionise the treatment of the most serious hospital-acquired infections.
Alchemia Managing Director Dr Tracie Ramsdale said the results proved that
Alchemia’s compounds were highly active against multi-drug resistant
organisms by specifically acting through an unchallenged mechanism of
action.
“These findings could potentially be the most extraordinary scientific
development in several decades in the fight against a broad range of multidrug
resistant gram-positive bacterial strains,” she said.
“Effectively these test results verify that our compounds are suitable
candidates for treating hospital-acquired infections. In the US alone, the
healthcare bill associated with treating hospital-acquired infections exceeds
$US4.5 billion each year.”
Dr Ramsdale said there were very few novel antibacterials in the global
pipeline targeted at treating multi-drug resistant bacteria in hospitals.
“Not only are there very few antibiotics in development but bacterial
resistance to existing drugs ‘of last resort’ is rapidly increasing – creating a
serious health issue for the international community,” she said.
The recent study was conducted by a world leader in microbial research – the
Antimicrobial Research Centre* at the University of Leeds. The results verified
that Alchemia’s compounds act by inhibiting transglycosylase (TG) enzyme
activity, preventing the bacteria from building new cell walls and resulting in
its eventual death.
Dr Ramsdale said the results marked an exciting scientific breakthrough for
Alchemia as no antibacterial drugs were available for human use that directly
inhibited the TG enzyme.
She said Alchemia would proceed immediately to study the efficacy of its
compounds in animal models of resistant bacterial infections.
“We would expect to receive the efficacy results from the animal studies by
the end of 2004,” she said.
“Once efficacy has been proven we will actively seek to develop this project
with a suitable partner who will undertake the necessary human clinical
trials.”
Alchemia’s antibacterial compounds have displayed significant activity
against clinical isolates of multi-drug resistant Gram-positive bacteria, such
as Staphylococcus aureus (MRSA) and Enterococcal (VRE).
These exciting new results will be presented by Alchemia on October 27th at
the major US Biotechnology Conference hosted by Rodman and Renshaw in
New York.

ENDS

**tommy** · 21-10-2004, 05:26 PM

Just sold my entire holdings @0.77, was too good to let this pass[

]

Will get back into this company again when it gets cheaper in the future, as biotechs tend to be quite price volatile.

Happy trading all

**tommy** · 21-10-2004, 06:09 PM

UP 64.15%....WTF?!

Think I sold mine too early[V]

**tommy** · 21-10-2004, 07:30 PM

Closed at $0.830, a 56.60% increase today.

Was anyone following this stock today?

ABN AMRO has 12 month target price of $1.15 in an old report dated 17 June 2004 as posted on Alchemia's website at

http://www.alchemia.com.au/media/ABN...17June2004.pdf

but now it looks a bit overvalued for a company with no cashflow... I suppose that's the nature of bubbly biotechs? Does anyone have any insight into ACL? I'm no biotech expert so I assumed I was going to take a long-term investment approach but the trade off is opportunity cost... IMHO, I think this is a company with great potential in a few years time but I would like to hear what others think!

All positive and negative opinions welcome

**tommy** · 14-02-2005, 06:50 PM

Haven't been any interesting news from ACL of late, and understandably the share price is starting to fall due to impatience on the part of holders (now below 70c)... not worth holding on to this HIGH RISK stock for months consdering the opportunity costs in the current market, I suppose!

Having said that, I personally think this is a stock worth keeping an eye on to buy on the cheap if you like bubbly biotechs, especially if it hits below 60c, preferably in mid-50s. Hoping for a further price fall to reenter soon

Of note,ABN Amro still has price target of $1.15 accoridng to Dec 2004 report.
http://www.alchemia.com.au/media/ABN..._10Dec2004.pdf

Am I the only one interested in this lemon here? Your thoughts will be appreciated

**tommy** · 01-04-2005, 01:19 PM

Damn,was waiting for ACL to drop to $0.55 to buy in again but bounced subsequent to following announcement yesterday...
____________

31 March 2005

ASX / MEDIA ANNOUNCEMENT

Alchemia awarded $7.8 million Australian Government GranAlchemia Grant

Australian biotechnology company Alchemia Limited (ASX: ACL) today announced it had been notified of its successful application for a $7.8 million research and development (R&D) grant under the Federal Government’s Pharmaceutical Partnerships Program (P3 Scheme).

The P3 grant entitles Alchemia to funding of up to approximately $7.8 million over three years starting from 1 July 2005 to support a number of its drug development
projects, dependent on the company meeting forecast R&D expenditure for the period.

Alchemia Chief Executive Officer Dr Tracie Ramsdale said the P3 grant was a major boost for the company, providing additional funding for the company’s planned R&D
activities for its advanced and early-stage drug discovery programs over the coming three years.

“This is the fourth Australian Government grant awarded to Alchemia since the company’s inception in 1995. We are enormously grateful for the strong support of the Australian Government and for the continued recognition of our promising drug development programs,” she said.

Alchemia drug development and commercialisation projects that are covered by the

P3 grant include:
Anti-cancer program — formal preclinical studies of Alchemia's novel angiogenesis inhibitor ACL 16907 required for an Investigational New Drug (IND) application planned by the end 2005 and subsequent Phase I/II clinical trials
Antibacterial program — optimisation of a series of novel antibacterial agents shown to be highly active against multi-drug resistant bacteria in vitro, establishing efficacy in suitable animal models of infection and formal preclinical
studies in order to start Phase I clinic l trials
Identification and evaluation of preclinical development candidates in other therapeutic areas arising from Alchemia’s VAST#63195; drug discovery platform
including Age-related Macular Degeneration (somatostatin agonists), Chronic pain (mu-opioids) and Obesity (melanocortins, MCH).

Alchemia was awarded the grant under the second round of the P3 scheme, under which $150 million has been provided on a competitive basis to companies undertaking pharmaceutical R&D activity in Australia.

ENQUIRIES: RELEASED BY:
Dr. Tracie Ramsdale Ms Josie Brophy
Alchemia Limited Phillips Group
Chief Executive Officer Tel: 61-7-3230-5000
Tel: 61-7-3340-0200

About Alchemia

Alchemia is a drug discovery company with a novel carbohydrate platform technology focused on the development of a generic Synthetic Heparin and on discovering a pipeline of oncology and antibiotic therapeutics. Alchemia has leveraged its carbohydrate chemistry expertise to develop a more efficient,
economical manufacturing process which Alchemia believes will ensure its generic Synthetic Heparin will be cost competitive with Arixtra® and other heparin-related drugs, providing Alchemia with a potentially significant market share of the
$US3 billion worldwide heparin market.
Alchemia’s generic synthetic heparin is being developed in collaboration with manufacturing partner, The Dow Chemical Company and marketing partner, American Pharmaceutical Partners and is expected to be launched in the US in 2008.
For further information on Alchemia’s drug discovery projects please refer to the company’s 2004/05 half yearly report available at www.alchemia.com.au

**utedog** · 04-04-2005, 01:26 PM

I've been watching this one also tommy and was waiting for the drop from the highs of last year. I'm no expert but I like this one and what they are doing. Good value below 65c i think. Have a look at BDM also, they are cheap at the moment.

regards
utedog

**tommy** · 04-04-2005, 02:44 PM

Hi Utedog,

I'm waiting to re-enter ACL below 60c, I think the opportunity will arise soon in the current climate considering this is an easily-battered stock when the bear is on the rise... cheers for info on BDM, will do some research on this too, looks interesting!